April Calvert, NP
Gerontology · Jackson, MSNPI 1609389436
Payments from drug & device makers
What this record shows
Almost everything reported here is food and beverage — 99.1% of the total across 111 separate payments, which is the pattern of a clinician who attends manufacturer presentations rather than one with a consulting arrangement. 30 manufacturers reported payments, led by Lilly USA, LLC at 26.1% of the total.
Across 111 payments — averaging $19.51 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- Lilly USA, LLC$566
- Tandem Diabetes Care, Inc.$300
- Abbott$236
- Bayer$177
- AstraZeneca$97
- Salix Pharmaceuticals, A Division Of Bausch Health US, LLC$70
- plus $719 from 24 others
What the payments were for
- Food & beverage$2,14699%
- Other$201%
Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| Lilly USA, LLC | 26 | $566 |
| Tandem Diabetes Care, Inc. | 14 | $300 |
| Abbott | 10 | $236 |
| Bayer | 9 | $177 |
| AstraZeneca | 5 | $97 |
| Salix Pharmaceuticals, A Division Of Bausch Health US, LLC | 4 | $70 |
| Sanofi-aventis U.S. LLC | 4 | $68 |
| Johnson & Johnson(2 entities) | 4 | $62 |
| Pfizer | 3 | $58 |
| Chiesi USA, Inc. | 3 | $56 |
| Novo Nordisk | 4 | $53 |
| Xeris Pharmaceuticals, Inc. | 2 | $42 |
| Corcept Therapeutics | 2 | $40 |
| Dexcom, Inc. | 2 | $39 |
| Sequel Med Tech, LLC | 2 | $33 |
| Takeda Pharmaceuticals U.S.A., Inc. | 2 | $31 |
| Insulet Corporation | 2 | $30 |
| AbbVie | 1 | $23 |
| Merck | 1 | $20 |
| Radius Health, Inc. | 1 | $18 |
| Amgen | 1 | $18 |
| Recordati_rare_diseases_inc. | 1 | $16 |
| Sobi, Inc | 1 | $15 |
| Boston Scientific | 1 | $15 |
| Idorsia Pharmaceuticals US Inc | 1 | $15 |
| Averitas Pharma Inc. | 1 | $15 |
| Amarin Pharma, Inc. | 1 | $13 |
| Amneal Pharmaceuticals LLC | 1 | $13 |
| IBSA Pharma Inc. | 1 | $12 |
| Medtronic | 1 | $12 |
What the payments were tied to
Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.
- MOUNJARO$246
How this compares
$2,166 in reported general payments places this provider in the 70th percentile of 66 gerontology providers in Mississippi.
Medicare billing
What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| MounjaroTirzepatide | 290 | $390,688 |
| OzempicSemaglutide | 103 | $165,315 |
| JardianceEmpagliflozin | 83 | $101,936 |
| FarxigaDapagliflozin Propanediol | 86 | $77,332 |
| TrulicityDulaglutide | 37 | $63,413 |
| Toujeo Max SolostarInsulin Glargine,hum.Rec.Anlog | 57 | $55,490 |
| Soliqua 100-33Insulin Glargine/Lixisenatide | 29 | $36,291 |
| Humalog Kwikpen U-200Insulin Lispro | 12 | $23,335 |
| Tresiba Flextouch U-100Insulin Degludec | 20 | $15,984 |
| Toujeo SolostarInsulin Glargine,hum.Rec.Anlog | 33 | $13,023 |
| Tresiba Flextouch U-200Insulin Degludec | 11 | $10,004 |
| Novolog FlexpenInsulin Aspart | 41 | $8,193 |
| HumalogInsulin Lispro | 12 | $5,002 |
| Humalog Kwikpen U-100Insulin Lispro | 21 | $4,516 |
| Lantus SolostarInsulin Glargine,hum.Rec.Anlog | 16 | $2,263 |
Paid to pharmacies, not to this prescriber.
Companies that both paid and supply prescribed drugs
These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.
| Company | Paid to this provider | Part D cost of their drugs |
|---|---|---|
| Lilly USA, LLCMounjaro, Trulicity, Humalog | $566 | $459,103339 claims |
| Novo NordiskOzempic | $53 | $165,315103 claims |
| AstraZenecaFarxiga | $97 | $77,33286 claims |
| Sanofi-aventis U.S. LLCSoliqua 100-33 | $68 | $36,29129 claims |
Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 70th percentile of 66 gerontology providers in Mississippi.
Other gerontology in Jackson
- Daniel WelchJackson$8K
- Lauren BuffingtonJackson$3K
- Flora GreenJackson$3K
- Sarah BallingerJackson$3K
- Shemina RansomJackson$3K
- Lacey MayfieldJackson$2K
- Ashley SabbatiniJackson$1K
- Gloria JaquesJackson$1K
- Roxane MoncureJackson$1K
- Tracey GrayerJackson$886
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
- Identity: NPPES NPI Registry, July 2026.